CorMedix Therapeutics Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash Position
Globe Newswire•02/11/2026•07:30 ET
0
Key Highlights
- ➤Cash and equivalents approximately $355 million as of September 30, 2026
- ➤CorMedix reaffirms 2026 total revenue guidance of $325 million-$345 million
- ➤CMS sets Q1 2027 DefenCath Add-on at $8.32 per dialysis session
- ➤CorMedix expects 2027 average Add-on rate above twice the current $2.37
- ➤DefenCath Add-on expected to decline in Q2 2027, then increase in Q3 and/or Q4
PARSIPPANY, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today provided a business update in advance of a conference call expected to be held on November 12, 2026 to discuss the Company’s complete quarterly financial performance.
Business Updates * CorMedix announces unaudited cash and cash equivalents on hand as of September 30, 2026 of approximately $355 million.
Get started
Create a free account to read the full story.